![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Agendia’s MammaPrint BluePrint Kit Obtains CE Mark
Agendia’s MammaPrint BluePrint Kit Obtains CE Mark
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
March 22, 2018
Irvine, California-based Agendia received a CE Mark for its next-generation sequencing-based MammaPrint BluePrint breast cancer recurrence and molecular subtyping kit.
MammaPrint analyzes 70 genes most connected with breast cancer recurrence to determine a low or high risk of cancer recurrence result, while BluePrint analyzes 80 genes which classify a patient’s breast cancer into functional molecular subtypes.
The device can aid physicians in personalizing treatment management for patients by identifying early-stage breast cancer in women that is at a genomic low or high risk for distant metastasis within five years.
Upcoming Events
-
21Oct